Danaher Corp
Close on Oct 30, 2026Market cap $163.25BP/E 41.2Yield –
Danaher Base Business Core Sales Growth by Quarter
Base Business Core Sales Growth (Legacy FY2021Q4–FY2023Q4: Base Business ex-COVID Testing & Vx/Tx) (%)
Danaher Base Business Core Sales Growth: -4.5% in Q4 2023, down 19.0 pts from a year earlier. That is the lowest of the 9 quarters on record here. No newer figure appears in the documents we track.
Where the Q4 2023 figure comes from
Source: Danaher IR — nongaap_2023Q4 ↗
Historical (Legacy) series reported continuously from Q4 2021 to the Q1 2024 definition break (when COVID transitioned to an endemic phase and the company ceased separately breaking out COVID vaccines/therapeutics).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Base Business Core Sales Growth (Legacy FY2021Q4–FY2023Q4: Base Business ex-COVID Testing & Vx/Tx) (%) | Year on year | Source |
|---|---|---|---|---|
| Q4 2023 | Dec 31, 2023 | -4.5% | -19.0 pts | Danaher IR — nongaap_2023Q4 ↗ |
| Q3 2023 | Sep 30, 2023 | -4.0% | -19.5 pts | Danaher IR — nongaap_ex_veralto ↗ |
| Q2 2023 | Jun 30, 2023 | 2.0% | -12.0 pts | Danaher IR — nongaap_ex_veralto ↗ |
| Q1 2023 | Mar 31, 2023 | 6.0% | -8.5 pts | Danaher IR — nongaap_ex_veralto ↗ |
| Q4 2022 | Dec 31, 2022 | 14.5% | +1.5 pts | Danaher IR — nongaap_ex_veralto ↗ |
| Q3 2022 | Sep 30, 2022 | 15.5% | – | Danaher IR — nongaap_ex_veralto ↗ |
| Q2 2022 | Jun 30, 2022 | 14.0% | – | Danaher IR — nongaap_ex_veralto ↗ |
| Q1 2022 | Mar 31, 2022 | 14.5% | – | Danaher IR — nongaap_ex_veralto ↗ |
| Q4 2021 | Dec 31, 2021 | 13.0% | – | Danaher IR — nongaap_ex_veralto ↗ |
Cite this data
StockData. (2026). Danaher Base Business Core Sales Growth (%), quarterly Q4 2021–Q4 2023 [Data set]. Compiled from Danaher SEC filings and investor materials. https://stockdatahq.com/stocks/dhr/kpis/base-biz-core-growth-legacy-total
See every metric in the Danaher KPI table. Data updated Nov 2, 2026.